Altimmune, Inc.(ALT)Earnings, Financials & Key RatiosAltimmune, Inc. (ALT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on capital markets is evidenced by a $672.0 million accumulated deficit and a persistent quarterly net loss trajectory that necessitates ongoing dilutive financing.
Altimmune, Inc. (ALT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Altimmune, Inc. (ALT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.18vs $0.25+28.0% | —vs $1,429 |
| Q2 2026 | Mar 5, 2026 | $0.27vs $0.25-8.0% | $26,000vs $556+4576.3% |
| Q4 2025 | Nov 6, 2025 | $0.21vs $0.29+27.6% | $5,000vs $560+792.9% |
| Q3 2025 | Aug 12, 2025 | $0.27vs $0.32+15.6% | $5,000vs $1,429+249.9% |
Recent stock market news and headlines for Altimmune, Inc. (ALT)
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Key metrics vs top competitors for Altimmune, Inc. (ALT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.08 | $271.83M | -3.08 | 105% | -214860.98% | -50.57% | — | |
| $38.71 | $4.49B | -12.13 | — | — | -71.31% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — | |
| $3.95 | $68.19M | -2.94 | — | -1070.26% | — | — | |
| $54.75 | $3.15B | -22.81 | — | — | -15.14% | — | |
| $50.01 | $3.05B | -27.33 | — | — | -21.04% | — |
Altimmune, Inc. (ALT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Altimmune, Inc. (ALT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Apr 24, 2026·SEC
Apr 16, 2026·SEC
Get notified when ALT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Altimmune, Inc. (ALT) stock FAQ — growth, dividends, profitability & financials explained
Altimmune, Inc. (ALT) reported $0.0M in revenue for fiscal year 2025. This represents a 94% decrease from $0.6M in 2005.
Altimmune, Inc. (ALT) grew revenue by 105.0% over the past year. This is strong growth.
Altimmune, Inc. (ALT) reported a net loss of $91.1M for fiscal year 2025.
Altimmune, Inc. (ALT) has a return on equity (ROE) of -50.6%. Negative ROE indicates the company is unprofitable.
Altimmune, Inc. (ALT) had negative free cash flow of $72.0M in fiscal year 2025, likely due to heavy capital investments.
